- Previous Close
12.94 - Open
12.79 - Bid 12.19 x 800
- Ask 12.73 x 800
- Day's Range
12.35 - 12.85 - 52 Week Range
11.73 - 34.32 - Volume
488,937 - Avg. Volume
584,744 - Market Cap (intraday)
616.869M - Beta (5Y Monthly) 1.16
- PE Ratio (TTM)
-- - EPS (TTM)
-0.07 - Earnings Date Jul 30, 2024 - Aug 5, 2024
- Forward Dividend & Yield 0.24 (1.93%)
- Ex-Dividend Date May 31, 2024
- 1y Target Est
12.83
Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO; and nutricentials skin care products. The company also provides wellness products, such as LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
www.nuskin.com3,700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NUS
Performance Overview: NUS
Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NUS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NUS
Valuation Measures
Market Cap
616.87M
Enterprise Value
953.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.32
Price/Book (mrq)
0.76
Enterprise Value/Revenue
0.50
Enterprise Value/EBITDA
7.37
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.17%
Return on Assets (ttm)
4.34%
Return on Equity (ttm)
-0.39%
Revenue (ttm)
1.9B
Net Income Avi to Common (ttm)
-3.31M
Diluted EPS (ttm)
-0.07
Balance Sheet and Cash Flow
Total Cash (mrq)
230.66M
Total Debt/Equity (mrq)
83.12%
Levered Free Cash Flow (ttm)
145.74M